Goldman Sachs Group Inc. acquired a new stake in shares of Kura Oncology, Inc. (NASDAQ:KURA) during the first quarter, according to its most recent 13F filing with the SEC. The fund acquired 60,530 shares of the company’s stock, valued at approximately $533,000. Goldman Sachs Group Inc. owned 0.31% of Kura Oncology at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its stake in shares of Kura Oncology by 25.4% in the fourth quarter. Renaissance Technologies LLC now owns 30,600 shares of the company’s stock worth $181,000 after buying an additional 6,200 shares in the last quarter. Nationwide Fund Advisors acquired a new stake in shares of Kura Oncology during the first quarter worth approximately $136,000. Segantii Capital Management Ltd acquired a new stake in shares of Kura Oncology during the first quarter worth approximately $120,000. Morgan Stanley boosted its stake in shares of Kura Oncology by 175.5% in the first quarter. Morgan Stanley now owns 430,428 shares of the company’s stock worth $3,788,000 after buying an additional 274,166 shares in the last quarter. Finally, Oppenheimer & Co. Inc. boosted its stake in shares of Kura Oncology by 14.7% in the first quarter. Oppenheimer & Co. Inc. now owns 12,500 shares of the company’s stock worth $110,000 after buying an additional 1,600 shares in the last quarter. 51.08% of the stock is owned by hedge funds and other institutional investors.
Shares of Kura Oncology, Inc. (NASDAQ KURA) traded up 4.00% during mid-day trading on Monday, reaching $6.50. 64,314 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $8.75 and its 200-day moving average price is $8.63. The company’s market capitalization is $129.92 million. Kura Oncology, Inc. has a one year low of $4.00 and a one year high of $12.10.
Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Monday, August 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.03. On average, equities analysts expect that Kura Oncology, Inc. will post ($1.60) earnings per share for the current year.
A number of brokerages have commented on KURA. Zacks Investment Research raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. Citigroup Inc. set a $13.00 target price on shares of Kura Oncology and gave the company a “buy” rating in a report on Tuesday, August 8th. Oppenheimer Holdings, Inc. set a $16.00 target price on shares of Kura Oncology and gave the company a “buy” rating in a report on Wednesday, June 14th. Leerink Swann reaffirmed an “outperform” rating and set a $18.00 target price (up from $16.00) on shares of Kura Oncology in a report on Thursday, August 10th. Finally, Cann reaffirmed a “buy” rating and set a $16.00 target price on shares of Kura Oncology in a report on Monday, May 15th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $14.60.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
